Get started
Author

Abirami Seetharaman

Observed name: Seetharaman, Abirami
ORCID: 0000-0002-2981-1726
Observed ORCID: 0000-0002-2981-1726
OpenAlex ID: A5059155456
Charge-defect tuned PVDF based ternary biocompatible composite as skin touch actuated single electrode triboelectric nanogenerator for wireless healthcare monitoring
2024 · Abhishek Sasmal, Abirami Seetharaman, et al. · Chemical Engineering Journal · 42
Quercetin-loaded nanoarchaeosomes for breast cancer therapy: a ROS mediated cell death mechanism
2024 · Subastri Ariraman, Abirami Seetharaman, et al. · Materials Advances · 23
Doxorubicin loaded thermostable nanoarchaeosomes: a next-generation drug carrier for breast cancer therapeutics
2024 · Kaviya Vijayalakshmi Babunagappan, Abirami Seetharaman, et al. · Nanoscale Advances · 22
PDF
Immunotherapy for cervical cancer: Can it do another lung cancer?
2018 · Priya Ramanathan, Hemavathi Dhandapani, et al. · Current Problems in Cancer · 12
Dendritic cells matured with recombinant human sperm associated antigen 9 (rhSPAG9) induce CD4+, CD8+ T cells and activate NK cells: a potential candidate molecule for immunotherapy in cervical cancer
2021 · Hemavathi Dhandapani, Hascitha Jayakumar, et al. · Cancer Cell International · 9
PDF
Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer
2025 · Inemai Ezhil, Abirami Seetharaman, et al. · Molecular Cancer Therapeutics · 6
Elucidating shape-mediated drug carrier mechanics of hematite nanomaterials for breast cancer therapeutics
2024 · Kaviya Vijayalakshmi Babunagappan, Thilak Raj, et al. · Journal of Materials Chemistry B · 6
Combination of IDO1high and CCL19low expression in the tumor tissue reduces survival in HPV positive cervical cancer
2021 · Hascitha Jayakumar, Abirami Seetharaman, et al. · Journal of Reproductive Immunology · 6
Nanoarchaeosomes loaded with tumor antigens elicit antigen-presenting cell activation and T cell response for cervical cancer immunotherapy
2025 · Abirami Seetharaman, Parimalanandhini Duraisamy, et al. · Materials Advances · 3
PDF
Transcriptome Analysis of Human Pancreatic Stellate Cells Co-cultured With PAK1-Modulated Cells Revealed the Role of Cytokine Pathway in Tumor Microenvironment
2025 · Sridevi Duggirala, Vaishnavi Balasubramanian, et al. · Pancreas · 2
Autologous cervical tumor lysate pulsed dendritic cell stimulation followed by cisplatin treatment abrogates FOXP3+ cells in vitro
2021 · Hemavathi Dhandapani, Abirami Seetharaman, et al. · Journal of Gynecologic Oncology · 2
PAK1-mediated phosphorylation of ARGLU1 promotes tumorigenic potential of breast cancer
2026 · Srikanth Swamy Swaroop B, Prarthana Gopinath, et al. · Journal of Biological Chemistry
PELP1 expression is associated with disease progression in inflammation-driven oral cancer
2026 · Vedhashree Somashankar, Roshni Saravanan, et al. · Clinical & Translational Oncology
Supplementary Figure S11 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer
2026 · Inemai Ezhil, Abirami Seetharaman, et al.
Supplementary Figure S6 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer
2026 · Inemai Ezhil, Abirami Seetharaman, et al.
Supplementary Figure S15 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer
2026 · Inemai Ezhil, Abirami Seetharaman, et al.
Supplementary Figure S14 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer
2026 · Inemai Ezhil, Abirami Seetharaman, et al.
Supplementary Figure S9 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer
2026 · Inemai Ezhil, Abirami Seetharaman, et al.
Supplementary Figure S12 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer
2026 · Inemai Ezhil, Abirami Seetharaman, et al.
Supplementary Figure S3 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer
2026 · Inemai Ezhil, Abirami Seetharaman, et al.
Supplementary Table S1 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer
2026 · Inemai Ezhil, Abirami Seetharaman, et al.
Supplementary Figure S8 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer
2026 · Inemai Ezhil, Abirami Seetharaman, et al.
Supplementary Figure S7 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer
2026 · Inemai Ezhil, Abirami Seetharaman, et al.
Supplementary Figure S2 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer
2026 · Inemai Ezhil, Abirami Seetharaman, et al.
Supplementary Figure S4 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer
2026 · Inemai Ezhil, Abirami Seetharaman, et al.
Works count: 57
Citation count: 133
H-index: 6
I10-index: 4
Year
Topic
Type